Holly Hunsberger, PhD


Behavioral Neuroscientist (she/her)


Curriculum vitae


hh2694​@cumc​.columbia​.edu

646-774-7316

Psychiatry/Systems Neuroscience


Columbia University/ New York State Psychiatric Institute


1051 Riverside Drive, Unit 87
736 KOLB Annex



Glutamate's role in Alzheimer's disease


I collaborated with Dr. Greg Gerhardt, inventor of the MEA, to show for the first time that glutamate neurotransmission was altered in an AD mouse model and that these neurochemical changes correlated with behavior. Subsequently, we administered an FDA approved drug for treatment of ALS, Riluzole, which acts on the glutamate system. Riluzole improved glutamate regulation, cognitive performance, and AD pathology. This study was an important first step in the development of an off-label, proof-of-concept, investigation of Riluzole in AD patients. My work studying glutamate’s role in AD earned me an editorial highlight in the Journal of Neurochemistry and inspired me to take an interest in finding other therapeutic targets for AD. 

Publications


P301L tau expression affects glutamate release and clearance in the hippocampal trisynaptic pathway


Hunsberger HC, Rudy CC, Batten SR, Gerhardt GA, Reed MN


Journal of Neurochemistry , vol. 25(4), 2014, pp. 331-335


Riluzole rescues glutamate alterations, cognitive deficits, and tau pathology associated with P301L tau expression


Hunsberger HC, Weitzner DS, Rudy CC, Hickman JE, Libell EM, Speer RR, Gerhardt GA, Reed MN


Journal of Neurochemistry , vol. 135(2), 2015, pp. 381-394


Riluzole rescues alterations in rapid glutamate transients in the hippocampus of rTg4510 mice


Hunsberger HC, Hickman JE, Reed MN


Metabolic Brain Disease, vol. 31(3), 2016, pp. 711-715


Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models


Hunsberger HC, Setti SE, Heslin RT, Quintero JE, Gerhardt GA, Reed MN


Journal of Visualized Experiments , 2017